This hydrophobic to hydrophilic shift reduced the hydrophobic stabilization and subsequently the formed carboxylic acid interferes with hydrogen bonding and electrostatic interactions
: Phase III REGENCY trial demonstrated 46.4% complete renal response vs 33.1% with standard therapy alone Significant improvement in multiple secondary endpoints including proteinuria reduction Consistent safety profile with known oncology indications First anti-CD20 monoclonal antibody with phase III evidence in lupus nephritis : - More convenient administration schedule: four initial doses in first year, then twice-yearly infusions - Option for 90-minute infusions after initial dose - Maintains standard therapy alongside biologic treatment - Requires monitoring for infections and infusion-related reactions "This approval provides a much-needed new option for these patients," said Levi Garraway, MD, PhD, chief medical officer at Roche, highlighting the significant unmet need in lupus nephritis management
These compounds target overlapping receptor systems, and combining them dramatically increases the risk of severe gastrointestinal side effects without proportional benefit
On the other hand, inability to eat even small meals, severe nausea lasting more than a few days after dose escalation, and significant dizziness or lightheadedness suggest the dose is too high